More recently, AMN treatments in other cancer cell models have revealed additional potential targets, including the mammalian target of rapamycin complex 1 (mTORC1) and cyclin-dependent kinase 4 (CDK4) inhibition, respectively, while exhibiting significantly reduced toxicity towards normal tissue and cells [17,18,19]. This evidence concerns the gene CDK4 and cancer.